

Adenosine reduces agonist-induced production of inositol phosphates in rat aorta

C. J. LONG* AND T. W. STONE

Department of Physiology, St George's Hospital Medical School, University of London, London SW17 0RE, UK

In rat aortic strips rendered permeable with digitonin, inositol trisphosphate induced an efflux of ^{45}Ca from the tissue. This release was not affected by adenosine. In tissues not treated with digitonin the contents of inositol trisphosphate (IP_3) and its metabolite inositol 1-phosphate (IP_1) were significantly enhanced by noradrenaline in the lithium-treated rat aorta. Adenosine was without effect on levels of IP_1 or IP_3 in tissues which had not been pretreated with noradrenaline, however, the noradrenaline-enhanced tissue content of IP_1 was reduced by adenosine in a dose-dependent manner. The reduction in IP_1 content by adenosine was enhanced by the uptake blocker dipyridamole ($10\ \mu\text{M}$) and was blocked by the adenosine receptor antagonist 8-phenyltheophylline ($10\ \mu\text{M}$). Adenosine may therefore lower production of inositol phosphates and thus reduce the stimulated release of calcium from intracellular stores. It is proposed that a reduction in phosphatidylinositol turnover may play a role in adenosine-mediated relaxation of blood vessels.

Adenosine has been recognized as possessing vasodilatory activity since Drury & Szent-Gyorgi (1929) demonstrated that this purine lowered arterial blood pressure to a degree which could not be entirely explained by a reduction in cardiac output. Adenosine actions on vascular muscle have been attributed to a reduction in cellular calcium uptake (Schnaar & Sparks 1972; Belardinelli et al 1979; van Breemen & Casteels 1974; Schrader et al 1975). Direct measurements of calcium fluxes have been performed by Guthrie & Naylor (1967) using mammalian atria to demonstrate a decrease in inward calcium flux with adenosine, and by Dutta et al (1980) who were unable to show any effect on calcium uptake in coronary artery. In view of this confusion we have considered the possibility that adenosine may modify calcium availability indirectly, by interfering with intracellular second messengers which affect calcium influx or intracellular release. An increased turnover of phosphoinositides has been described in non-muscle cells in response to stimulation by secretagogues (Hokin & Hokin 1953; Michell 1975) ultimately increasing the formation of inositol 1,4,5-trisphosphate (IP_3) which has subsequently been shown to release calcium ions from endoplasmic reticulum (Streb et al 1983; Berridge & Irvine 1984). The increased formation of IP_3 has been shown to occur in vascular smooth muscle in response to pharmacomechanical stimulation such as noradrenaline (NA) (Legan et al 1985; Campbell et al 1985).

In the present study we have therefore sought to determine the effects of adenosine on inositol phosphate turnover as well as on the stimulation of calcium release from intracellular sites by inositol phosphates.

MATERIALS AND METHODS

Male Wistar rats (200–300 g) were killed by stunning and cervical dislocation. The thoracic aorta was rapidly removed into Krebs-Henseleit solution of the following composition (mM): NaCl 115, NaHCO_3 25, CaCl_2 2.5, KH_2PO_4 2.2, KCl 2, MgSO_4 1.2, glucose 10, pH 7.4 and gassed with 5% CO_2 in O_2 . The aorta was cleaned of adhering fat and connective tissue from the external surface and cut into a helical strip of approximate dimensions 15×4 mm. The strip was then denuded of endothelium by gently dragging the tissue, luminal surface down over moistened filter paper for 5–6 short strokes. This procedure was previously determined to be effective in removing endothelium since it abolished relaxant responses to acetylcholine (ACh) but had little effect on the relaxant properties of adenosine. Furthermore, histological studies based on the method of Griffith et al (1984) showed a practically complete removal of the endothelium by this procedure.

Release of ^{45}Ca from tissue

Aortic strips, freed of endothelium, were mounted under 0.8 g tension in calcium-free Krebs solution and contractile responses to NA ($100\ \mu\text{M}$) were obtained. Digitonin and collagenase were added to the bathing medium to final concentrations of

* Correspondence and present address: Dept. of Pharmacology L521, Smith Kline and French Laboratories, 709, Swedeland Rd, Swedeland, PA 19479, USA.




FIG. 2. The release of ^{45}Ca from a digitonin-treated aortic strip. The tissue was washed where indicated by the dot below the axis and then adenosine $300\ \mu\text{M}$ (AD), inositol $10\ \mu\text{M}$ (INOS), noradrenaline $1\ \mu\text{M}$ (NA) or IP_3 $5\ \mu\text{M}$ were included 4 min later.

tivity may be due to label washing off membranes, to continuous basal release from organelles either as their normal activity or as a consequence of damage, or a combination of these factors. The baseline did, however, show a decay during the course of the experiment to approximately $10\ \text{d min}^{-1}$ /aliquot.

Noradrenaline ($1\ \mu\text{M}$), inositol ($10\ \mu\text{M}$) and adenosine ($300\ \mu\text{M}$) were added separately to the incubation medium with a wash between applications. None of these agents produced any demonstrable effect on release of label. IP_3 ($5\ \mu\text{M}$), however, readily evoked a large release of ^{45}Ca into the incubation medium. The release was rapid, commencing within at least 1 min of the application of the agent and was sustained for approximately 15 min (Fig. 2).

Actions of adenosine on release of ^{45}Ca

Table 1 summarizes the release of ^{45}Ca obtained from digitonin-treated preparations in response to two consecutive challenges with IP_3 ($5\ \mu\text{M}$). A release of ^{45}Ca was observed with both challenges, however the second challenge released somewhat less label than the first presumably due to partial depletion of

Table 1. ^{45}Ca release from digitonin-treated aortic smooth muscle.

Agent added before B	Release ratio (B/A $\times 100$)	n
Buffer	63.8 ± 8.6	6
Adenosine $300\ \mu\text{M}$	59.6 ± 5.1	6
Adenosine deaminase $5\ \text{u mL}^{-1}$	57.9 ± 14.2	4

The digitonin-treated tissue was challenged on two occasions, A and B. Adenosine, adenosine deaminase or buffer was included before the second (B) challenge.

There were no significant differences from the control values at $P < 0.05$ (*t*-test).

intracellular stores. Results of release are expressed as the ratio of the two challenges with IP_3 . Neither adenosine nor adenosine deaminase (to destroy any endogenous adenosine) produced any change in the ratio of the IP_3 -induced calcium release.

Effects on inositol phosphate content

The Dowex columns used for chromatography were characterized with authentic standards of inositol, IP_1 and IP_3 . Greater than 98% of each standard applied to the column was recovered during the entire elution procedure and at least 95% of each standard was recovered within a single elution component. Chromatograms of the standards used are overlaid in Fig. 3 confirming that the protocol affords the resolution of these moieties into discrete fractions.




FIG. 3. The elution profile of inositol derivatives from a Dowex (1-X8) column. ∇ [^3H]inositol, \circ [^3H]IP $_1$ and \square [^{32}P]IP $_3$. The legend for the eluant corresponds to the legend for fractions in Table 2.

There was no significant change in the radiolabel content of fractions A or B with any of the experimental interventions used. The radiolabel content of fraction C, however, in which IP_1 was eluted from the columns was increased almost five-fold in response to noradrenaline ($1\ \mu\text{M}$). Smaller, but statistically significant, increases in labelling of fractions D and E were also noted on application of noradrenaline ($1\ \mu\text{M}$). These fractions have been associated with IP_3 and the higher phosphates of inositol, respectively (Berridge et al 1982) (Table 2).

The enhancement of labelling of the IP_1 fraction by NA was reduced by adenosine in an apparently concentration-dependent manner. Dipyridamole ($10\ \mu\text{M}$) significantly potentiated the effect of a submaximal ($50\ \mu\text{M}$) concentration of adenosine (P

Table 2. Phosphatidylinositol metabolite fractions from rat aorta.

Fractions	A	B	C	D	E
(a) Control (n = 5)	237.6 ± 65.2	9.8 ± 4.0	19.4 ± 4.0	6.02 ± 3.8	8.4 ± 2.9
(b) + NA 1 µM (n = 5)	189.4 ± 76.1	5.4 ± 2.2	*93.9 ± 24.5	*18.3 ± 7.6	*16.2 ± 4.6
(c) + NA 1 µM, aden 300 µM (n = 4)	207.8 ± 84.7	8.6 ± 3.8	*42.7 ± 13.2	10.7 ± 5.2	13.8 ± 7.2
(d) + NA 1 µM, aden 50 µM (n = 4)	218 ± 62.3	6.7 ± 4.0	76.3 ± 12.7	16.9 ± 8.0	11.7 ± 6.1
(e) + NA 1 µM, aden 300 µM, dipyr 10 µM (n = 4)	246.9 ± 71.6	6.1 ± 3.8	40.9 ± 20.8	14.8 ± 5.6	12.3 ± 4.2
(f) + NA 1 µM, aden 50 µM, dipyr 10 µM (n = 4)	232.7 ± 42.1	4.8 ± 2.9	*48.2 ± 8.6	20.8 ± 11.7	10.1 ± 5.2
(g) + NA 1 µM, aden 300 µM, 8PT 10 µM (n = 5)	216.9 ± 49	14.2 ± 8.1	*71.8 ± 13.7	14.0 ± 3.4	9.8 ± 4.8
(h) + aden 300 µM (n = 4)	251 ± 47.8	6.9 ± 1.5	24.7 ± 8.1	9.9 ± 5.8	7.5 ± 3.6
(j) + NA 1 µM, 8PT 10 µM (n = 4)	222.1 ± 58.1	8.3 ± 5.9	87.9 ± 19.9	21.7 ± 8.2	10 ± 5.2

NA = noradrenaline; aden = adenosine; dipyr = dipyridamole; 8PT = 8-phenyltheophylline.

Values are mean ± s.e.m. in counts min⁻¹ mg tissue⁻¹.

Comparison between results was performed using a two-tailed *t*-test between the following rows: (b) and (h) with (a); (c), (d) and (j) with (b); (f) with (d); (g) with (c).

* Significant difference at *P* < 0.05. Fraction C includes inositol-1-phosphate.

< 0.05) indicating that the site of action of adenosine in this respect is likely to be extracellular. Furthermore, 8-phenyltheophylline (10 µM) reversed the adenosine-induced reduction in labelling of IP₁.

DISCUSSION

The sarcoplasmic reticulum (SR) of vascular smooth muscle is believed to store sufficient calcium to provide contraction when the ion is released (Bond et al 1984; Somlyo & Somlyo 1975; Garfield & Somlyo 1985). The results presented here clearly show that a specific release of ⁴⁵Ca was achieved on addition of IP₃ to preparations whose plasma membranes had been made hyperpermeable by digitonin and collagenase, a treatment which is thought not to affect intracellular membranes lacking cholesterol. Myo-inositol, adenosine or NA did not evoke any release of ⁴⁵Ca from the preparation. In addition, whilst the second challenge of IP₃ typically released approximately 60% of the label compared with the first challenge, adenosine did not affect this ratio. Since adenosine does not affect the sequestration of ⁴⁵Ca into the SR of this tissue (unpublished observations) the purine does not seem to have any direct effects on this organelle.

It has been demonstrated here that noradrenaline increases the tissue content of IP₁ during blockade of inositol 1-phosphatase by lithium (see also Legan et al 1985). Activation of α₁-adrenoceptors also increases inositol metabolism in rat vas deferens and tail artery (Fox et al 1985) as well as in the aorta. Campbell et al (1985) have correlated (indirectly) the hydrolysis of phosphatidylinositol with calcium flux and ultimately contraction in the rabbit aorta. Certainly IP₃ is associated with ⁴⁵Ca release from

intracellular sites as demonstrated here (see also Yamamoto & van Breemen 1985) and in a highly sophisticated experiment Somlyo et al (1985) showed that IP₃ not only induced calcium release in digitonin-treated smooth muscle fibres, but that this was quantitatively sufficient to induce an increase in tone in the preparation. Phosphorylation of inositol is believed to occur subsequent to incorporation of the sugar into phosphatidylinositol (Hirasawa & Nishizuka 1985), consequently an adenosine-induced reduction in phosphatidylinositol turnover is inferred from the results presented here.

The adenosine receptor mediating this response is probably located within the plasma membrane since its effects could be prevented by the purine receptor antagonist 8-phenyltheophylline, furthermore the nucleoside uptake inhibitor dipyridamole increased the effect of adenosine at intermediate concentrations of the purine.

The ability of adenosine to reduce tissue levels of biologically relevant phosphates of inositol will in turn therefore reduce the quantity of calcium released from intracellular stores and the magnitude of agonist-induced contraction. We therefore propose that this phenomenon may be involved in the mechanism by which adenosine produces vasorelaxation. We have demonstrated (Long & Stone 1985) that adenosine is of lesser potency when acting versus contractions believed to be based upon wholly extracellular calcium. If IP₃ does indeed modulate intracellular calcium release an adenosine-induced reduction of IP₃ production may account for this observation on calcium sources. More recently, Kuno & Gardner (1987) have described activation of plasma membrane calcium channels by IP₃ which

naturally implies that increased free cytosolic calcium from enhanced PI turnover may not be of solely intracellular origin.

Adenosine's actions on second messenger function has been well-described with regard to adenylate cyclase where it has been noted that either an increase or a decrease in cAMP content may occur which is dependent upon the adenosine receptor subtype activated (van Calker et al 1979). Such an action might also occur with phosphatidylinositol metabolism, since whilst Rubio (1986) showed that adenosine enhanced the decrease in phosphatidylinositol monophosphate and bisphosphate in oxytocin-stimulated rat adipocytes, an apparently opposite action was demonstrated by Curnish et al (1986) in the frog sympathetic ganglion, in which adenosine inhibited phosphatidylinositol turnover. Such results imply that adenosine may therefore exhibit actions upon multiple second messenger systems. Hollingsworth & Daly (1985) have discussed a possible interrelationship between cAMP accumulation and phosphatidylinositol turnover since diacylglycerols generated after hydrolysis of the inositol group stimulated protein kinase C which may lead to an enhanced responsiveness of adenylate cyclase upon stimulation. An interrelationship between cAMP and cGMP has already been speculated upon by Terasaki & Appleman (1975); the inclusion of a further level of modulation of second messenger function would considerably complicate the understanding of function and action of these moieties.

Acknowledgements

We are grateful to the British Heart Foundation for financial support.

REFERENCES

- Belardinelli, L., Rubio, R., Berne, R. M. (1979) *Pflugers Arch.* 380: 19-27
 Berridge, M. J., Irvine, R. F. (1984) *Nature* 312: 315-321
 Berridge, M. J., Downes, C. P., Hanley, M. R. (1982) *Biochem. J.* 206: 587-595
 Bond, M., Kitazawa, T., Somlyo, A. P., Somlyo, A. V. (1984) *J. Physiol.* 355: 677-695
 Campbell, M. D., Deth, R. C., Payne, R. A., Honeyman, T. W. (1985) *Eur. J. Pharmacol.* 116: 129-136
 Curnish, R. R., Bencherif, M., Berne, R. M. (1986) *Pflugers Arch.* 407: S41
 Drury, A. N., Szent-Gyorgi, A. (1929) *J. Physiol.* 68: 212-237
 Dutta, P., Mustafa, S. J., Jones, A. W. (1980) *Fed. Proc.* 39: 530
 Fox, A. W., Abel, P. W., Minneman, K. P. (1985) *Eur. J. Pharmacol.* 116: 145-152
 Garfield, R. E., Somlyo, A. P. (1985) in: Grover, A. K., Daniel, E. E. (eds) *Calcium and Smooth Muscle Contractility*. Humana Press, Clifton, N.J. pp 1-36
 Griffith, T. M., Henderson, A. H., Hughes Edwards, D., Lewis, M. J. (1984) *J. Physiol.* 351: 13-24
 Guthrie, J. R., Naylor, W. G. (1967) *Arch. Int. Pharmacodyn.* 170: 249-255
 Hirasawa, K., Nishizuka, Y. (1985) *Ann. Rev. Pharmacol.* 25: 147-170
 Hokin, M. R., Hokin, L. E. (1953) *J. Biol. Chem.* 203: 967-977
 Hollingsworth, E. B., Daly, J. W. (1985) *Biochim. Biophys. Acta* 847: 207-216
 Kuno, M., Gardner, P. (1987) *Nature* 326: 301-304
 Legan, E., Chernow, B., Parrillo, J., Roth, B. L. (1985) *Eur. J. Pharmacol.* 110: 389-390
 Long, C. J., Stone, T. W. (1985) *Br. J. Pharmacol.* 85: 8P
 Michell, R. H. (1975) *Biochim. Biophys. Acta* 415: 81-147
 Rubio, R. (1986) *Pflugers Arch.* 407, suppl. 1: S38
 Schnarr, R. L., Sparks, H. V. (1972) *Am. J. Physiol.* 223: 223-228
 Schrader, J., Rubio, R., Berne, R. M. (1975) *J. Mol. Cell. Cardiol.* 7: 427-433
 Somlyo, A. P., Somlyo, A. V. (1975) in: D. M. Paton (ed.) *Methods of Pharmacology*. Vol. 3, pp 3-45
 Somlyo, A. V., Bond, M., Somlyo, A. P., Scarpa, A. (1985) *Proc. Natl. Acad. Sci.* 82: 5231-5235
 Streb, H., Irvine, R. F., Berridge, M. J., Schulz, I. (1983) *Nature* 306: 67-69
 Terasaki, W. L., Appleman, M. M. (1975) *Metabolism* 24: 311-319
 van Breemen, C., Casteels, R. (1974) *Pflugers Arch.* 348: 239-245
 van Calker, D., Muller, M., Hamprecht, B. (1979) *J. Neurochem.* 33: 999-1005
 Yamamoto, H., van Breemen, C. (1985) *Biochim. Biophys. Acta* 130: 270-274